Article thumbnail

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

By Brian I. Rini, Darrel P. Cohen, Dongrui R. Lu, Isan Chen, Subramanian Hariharan, Martin E. Gore, Robert A. Figlin, Michael S. Baum and Robert J. Motzer
Topics: Articles
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
  2. Angiogenesis factors and preeclampsia.
  3. (2009). Arterial hypertension correlates with clinical outcome in colorectal cancer patients with first-line bevacizumab. Ann Oncol.
  4. (2008). Association of diastolic blood pressure (dBP) >= 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). Poster presentation at the 44th annual meeting of the American Society of Clinical Oncology.
  5. Clinical course of advanced non–small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
  6. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.
  7. Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G).
  8. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors.
  9. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance.
  10. (2009). Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma [published online ahead of print
  11. (2009). Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol.
  12. (2009). Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs.
  13. (2008). Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res.
  14. (2006). Hypertension and targeted therapy: part 1. Bevacizumab. Targeted Oncology.
  15. (2006). Hypertension and targeted therapy: part 2. Small molecule inhibitors of VEGF. Targeted Oncology.
  16. Hypertension as a predictive factor of sunitinib activity.
  17. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
  18. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
  19. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
  20. New guidelines to evaluate the response to treatment in solid tumors.
  21. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
  22. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
  23. (2009). Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res.
  24. (2010). Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs.
  25. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
  26. (2009). Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and metaanalysis. Acta Oncol.
  27. (2009). Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol.
  28. Sunitinib in patients with metastatic renal cell carcinoma.
  29. Sunitinib malate (SUTENT®) prescribing information.
  30. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
  31. (2008). The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol.
  32. Vascular endothelial growth factorinduced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants.
  33. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.